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BRIEF COMMUNICATION
Tat-NR2B9c prevents excitotoxic neuronal superoxide
production
Yanting Chen1,2,5, Angela M Brennan-Minnella2,5, Sunil Sheth2, Jamel El-Benna3,4 and Raymond A Swanson2
The Tat-NR2B9c peptide has shown clinical efficacy as a neuroprotective agent in acute stroke. Tat-NR2B9c is designed to prevent
nitric oxide (NO) production by preventing postsynaptic density protein 95 (PSD-95) binding to N-methyl-D-aspartate (NMDA)
receptors and neuronal nitric oxide synthase; however, PSD-95 is a scaffolding protein that also couples NMDA receptors to other
downstream effects. Here, using neuronal cultures, we show that Tat-NR2B9c also prevents NMDA-induced activation of neuronal
NADPH oxidase, thereby blocking superoxide production. Given that both superoxide and NO are required for excitotoxic injury,
the neuroprotective effect of Tat-NR2B9c may alternatively be attributable to uncoupling neuronal NADPH oxidase from NMDA
receptor activation.
Journal of Cerebral Blood Flow & Metabolism (2015) 35, 739–742; doi:10.1038/jcbfm.2015.16; published online 11 February 2015
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INTRODUCTION
Brain ischemia leads to acute cell death, in part through sustained
activation of N-methyl-D-aspartate (NMDA)-type glutamate recep-
tors (NMDAr) and the resulting production of nitric oxide (NO) and
superoxide.1,2 While neither NO or superoxide alone is highly
reactive or toxic, in combination they form peroxynitrite and
related free radical species that avidly react with lipids, proteins,
DNA, and other cell components to cause excitotoxic cell death.1,2
Postsynaptic density protein 95 (PSD-95) serves as a scaf-
folding protein for the clustering of synaptic receptors, ion
channels, and associated signaling proteins.3 It binds both to
neuronal NO synthase (nNOS) and to the NR2B subunits of
NMDAr.4 Targeted disruption of these binding interactions with a
Tat-conjugated peptide comprising the nine C-terminal residues
of NR2B blocks NMDA-induced NO production. This peptide,
termed ‘Tat-NR2B9c’ or ‘NA-1’ also blocks excitotoxic neuronal
death, reduces acute ischemic cell death in animal stroke models,
and has shown efficacy as a neuroprotective agent in clinical
stroke.2,5,6
Given the crucial role of NO in excitotoxic injury, the disruption
of NMDAr/nNOS interaction is a likely mechanism for the neuro-
protective effects observed with Tat-NR2B9c. However, superoxide
production by NADPH oxidase (NOX2) is equally required for
peroxynitrite formation and for excitotoxic and ischemic cell
death.1,2,7–9 These factors raise the possibility that disruption of
NMDAr/NOX2 interactions might also (or alternatively) contribute
to the mechanism of this promising stroke therapeutic. The
present studies confirm that Tat-NR2B9c blocks NMDA-induced
superoxide formation by a mechanism that prevents phosphor-
ylation of the NOX2 p47phox subunit.
MATERIALS AND METHODS
Materials
Studies were approved by the SFVAMC Animal Studies subcom-
mittee and conducted according to the current Guide for the Care
and Use of Laboratory Animals (Public Health Service Policy on
Humane Care and Use of Laboratory Animals). The Tat-NR2B9c
was a kind gift from M Tymianski, Toronto, Canada. The gp91ds-
Tat and scrambled sequence (control) peptides were purchased
from CPC Scientific (Sunnyvale, CA, USA). The control peptide
sequence was CSFNSYELGSLCYGRKKRRQRRR, with underlining
denoting the Tat component. All other reagents were purchased
from Sigma-Aldrich (St. Louis, MO, USA) except where noted.
Cell Cultures
Neuronal monocultures were prepared from the cortices of
embryonic mice as described.10 Studies were initiated in cultures
at days 10 to 12 in vitro by exchanging the culture medium with a
low-magnesium balanced salt solution.10 Peptides and drugs were
added from concentrated stocks 15 minutes before the addition
of NMDA.
Superoxide Detection and Immunostaining
Oxidation of dihydroethidium to fluorescent ethidium species
(Eth) was used to monitor intracellular superoxide levels as
described.10 The Eth signal was quantified as fluorescence
area ×mean intensity and normalized to cell number. Intracellular
calcium imaging was performed with Fura FF and quantified as
previously described.10 For immunostaining, cultures were fixed in
4% formaldehyde and incubated overnight with primary
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antibodies: anti-4-hydroxynonenal (Abcam, Cambridge, MA, USA);
anti-Ser139-Histone H2A.X (Cell Signaling Technology, Danvers,
MA, USA), or anti-Ser328 phospho-p47phox,11 together with mouse
anti-microtubule-associated protein 2 (Chemicon, Temecula, CA,
USA). Antibody binding was visualized with fluorescently-tagged
secondary antibodies and quantified as the mean fluorescence
intensity within the area defined by MAP-2 fluorescence (neurons).
Most studies were independently replicated by at least two
different observers, and in all cases the individual performing data
analysis was blinded to the experimental conditions.
Cell Death
Peptides and drugs were added from concentrated stocks 15
minutes before the addition of NMDA, and the NMDA was
removed by medium exchanges after 30 minutes. Twenty-four
hours later live neurons were identified by calcein green retention,
and dead neurons were identified by Hoeschst 33258.10 Live and
dead neurons were counted in three randomly chosen fields in
four wells per plate of each experiment, and results were
expressed as the percent of neurons that were dead.
Statistics
The ‘n’ for each study denotes the number of experiments, each
performed in independently generated cultures. Within each
experiment, each treatment condition was evaluated in at least
three culture wells, each assessed in three randomly identified
optical fields. Data are presented as means ± s.e.m. For cell death
results, statistical significance was evaluated using one-way
ANOVA with Dunnett’s test to compare multiple groups against
a single experimental group. For studies using fluorescence end-
points, statistical significance was evaluated using the Kruskal–
Wallis test with Dunnett’s test to compare multiple groups against
a single experimental or control group.
RESULTS
To determine whether NR2B binding to PSD-95 is required for
NMDAr-triggered superoxide production, we treated neuronal
cultures with 100 μmol/L NMDA for 30 minutes together with Tat-
NR2B9c over a range of concentrations and evaluated superoxide
formation by the dihydroethidium method. At the highest con-
centration (0.5 μmol/L), Tat-NR2B9c suppressed NMDA-induced
superoxide production by about 75% (Figures 1A and 1B). This
effect was comparable to that achieved with the gp91ds-Tat
peptide (Figures 1B and 1C), which prevents assembly of the
active neuronal NOX2 complex.10,12 By contrast, the nNOS
inhibitor L-NG-nitroarginine methyl ester (L-NAME) had no effect
on superoxide production. The inhibitory effect of Tat-NR2B9c on
NMDA-induced superoxide production was further confirmed by
imaging formation of the lipid peroxidation product, 4-hydro-
xynonenal (Figures 1D and 1E). Additional evidence that Tat-
NR2B9c prevents NOX2 activation was obtained by assessing
phosphorylation of the p47phox serine 328 residue, which is
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Figure 1. Tat-NR2B9c blocks N-methyl-D-aspartate (NMDA)-type glutamate receptors (NMDAr)-triggered superoxide production. (A)
Concentration-response curve. (B and C) Oxidized dihydroethidium (Eth fluorescence) in neuronal cultures. Scale bar= 20 μm. NMDA,
100 μmol/L; Tat-NR2B9c, 0.5 μmol/L; scrambled-sequence tat-conjugated peptide, 0.5 μmol/L; L-NG-nitroarginine methyl ester (L-NAME),
10μmol/L; gp91ds-Tat, 0.5 μmol/L. (D and E) Immunostaining (red) shows 4-hydroxynonenal formation. Green identifies neuronal processes
(MAP-2), and in merged images, blue identifies cell nuclei (DAPI, blue). All studies with n43; *Po0.05 versus NMDA.
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required for assembly of the functional NOX2 complex.11 NMDA
induced a marked increase in phospho-ser328 p47phox immunor-
eactivity in cultured neurons, and this increase was negated by co-
incubation with the Tat-NR2B9c (Figures 2A and 2B).
These results suggest that NR2B binding to PSD-95 is an
essential step linking NMDAr activation to NOX2 activation.
However, Tat-NR2B9c might alternatively impair NOX2 activation
by reducing NMDA-induced calcium influx. This possibility
was evaluated using the low-affinity calcium indicator Fura-FF.
Tat-NR2B9c was found to have no measurable effect on the rate or
magnitude of NMDAr-induced calcium influx (Figures 2C and 2D),
consistent with prior reports.5
NMDA-induced cell death is caused primarily by the formation
of peroxynitrite and related reactive oxygen species, which induce
DNA strand breaks and resultant activation of the poly(ADP-
ribose) polymerase cell death cascade.1,2 DNA strand breaks thus
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Figure 2. Tat-NR2B9c prevents N-methyl-D-aspartate (NMDA)-type glutamate receptor (NMDAr)-triggered NOX2 activation and DNA damage
but not calcium elevations. (A and B) Immunostaining (red) shows phosphorylation of NOX2 p47phox at Ser328. Conditions as in Figure 1; scale
bars= 20 μm. n= 4; *Po0.05 versus NMDA. (C) Representative traces of Fura FF ratio from single neurons show intracellular calcium changes
after exposure to NMDA (arrow) in neurons coincubated with or without Tat-NR2B9c. (D) Quantified results expressed as integrated calcium
change over 30minutes after addition of NMDA. n= 4 experiments, each with425 neurons. (E and F) Immunostaining (red) shows foci of γ-
H2A.X, which accumulates at DNA strand breaks. Blue counterstain (DAPI) shows nuclei. Scale bar= 20 μm; conditions as in Figure 1. n= 4,
*Po0.05 versus NMDA.
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provide a link between oxidative stress and cell death. Immunos-
taining for phosphorylated histone H2A.X (γ-H2A.X), which
accumulates at DNA strand breaks, showed that the NOX2
inhibitor gp91ds-Tat prevented NMDA-induced DNA breaks, and
that Tat-NR2B9c had comparable efficacy (Figures 2E and 2F).
Importantly, NMDA-induced DNA strand breaks were also
prevented by the nNOS inhibitor L-NAME, confirming that NO
production was suppressed by L-NAME under the conditions of
this study. Assessment of NMDA-induced cell death under these
same treatment conditions gave a parallel result; neuronal death
was significantly reduced by Tat-NR2B9c, gp91ds-Tat, or L-NAME
(Po0.05; n= 4), as previously observed.4,9,13
DISCUSSION
The Tat-NR2B9c peptide is one of the first neuroprotectant agents
to show efficacy in patients with acute stroke. Tat-NR2B9c is
designed to uncouple NO production from NMDAr activation by
blocking PSD-95 binding to NMDAr and nNOS. The present studies
show that Tat-NR2B9c also prevents NMDA-induced superoxide
formation by blocking p47phox phosphorylation, which is required
for assembly of the functional NOX2 complex.14 These findings
indicate that PSD-95 couples NMDAr to the signaling pathway
activating NOX2. Given that superoxide production is required for
excitotoxic cell death,1,2,8,9 the findings also suggest that the
neuroprotective effect of Tat-NR2B9c may be partly or wholly
attributable to its suppression of NOX2 activation.
The signaling pathway linking NR2B to NOX2 involves activation
of the atypical protein kinase PKCζ by phosphoinositide 3-kinase,
and subsequent phosphorylation of p47phox by PKCζ.10 This
process is regulated at multiple steps, and requires a conforma-
tional change in p47phox to expose the critical phosphorylation
sites.14 It has not yet been established how the binding of NMDA
(or glutamate) to NR2B activates phosphoinositide 3-kinase, but
prior reports indicate that PSD-95 provides a structural framework
for this interaction.15 Our results support this idea by showing that
the Tat-NR2B9c, which targets the PDZ domain of PSD-95, disrupts
the functional coupling between NR2B and NOX2. Although PDZ
domains are present on proteins other than PSD-95, specifically
the PDZ domains on PSD-95 are essential for the neuroprotective
effect of Tat-NR2B9c.4
The oxidation of dihydroethidium to fluorescent ethidium
species is specific for superoxide under cell-free conditions, but
metals and peroxidases present in cells can enable dihydroethi-
dium oxidation by other reactive oxygen species. Here, the
observation that NMDA-induced oxidation of dihydroethidium
was prevented by NOX2 inhibition confirmed that the observed
ethidium signal was attributable to superoxide.
Given that Tat-NR2B9c is known to uncouple NMDA receptors
from nNOS, we also considered the possibility that the inhibitory
effect of Tat-NR2B9c on NOX2 activation might in some way be
secondary to this inhibitory effect on nNOS. Indeed, the NOS
inhibitor L-NG-nitroarginine has been reported to block NMDA-
induced ethidium formation.16 However, the original study by
Lafon-Cazal et al8 found that L-NG-nitroarginine did not block
NMDA-induced superoxide formation, as evaluated by electron
paramagnetic resonance, and Brennan et al9 similarly found that
the NOS inhibitor L-NAME did not block NMDA-induced ethidium
formation. The present studies also show no effect of L-NAME on
superoxide production (Figures 1B and 1C). L-NAME was used here
at a concentration (100 μmol/L) previously shown to block
neuronal NO production,13,17 and inhibition of NO production
was confirmed by parallel studies showing that this concentration
of L-NAME prevented NMDA-induced DNA damage and cell
death. Together, these results indicate that the effect of Tat-
NR2B9c on superoxide production is not secondary to its effect on
NO production.
The present findings do not identify the mechanism by which
Tat-NR2B9c prevents superoxide production, but the effect of Tat-
NR2B9c on p47phox phosphorylation suggests an effect upstream
of this event. We propose that Tat-NR2B9c blocks p47phox phos-
phorylation through its disruption of PSD-95/NR2B binding, given
that NMDA-induced phosphorylation of p47phox requires activa-
tion of the PI3K pathway9,10 and that PI3K is coupled to NR2B by
PSD-95.15 Additional study will be required to confirm this
proposal; however, regardless of the mechanism, the present
results suggest that the inhibitory effect of Tat-NR2B9c on NMDA-
induced superoxide production may contribute to the neuropro-
tective effect of this promising therapeutic agent.
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